202 related articles for article (PubMed ID: 34337744)
1. Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all.
Kuiper RP; Hoogeveen PG; Bladergroen R; van Dijk F; Sonneveld E; van Leeuwen FN; Boer J; Sergeeva I; Feitsma H; den Boer ML; van der Velden VHJ
Br J Haematol; 2021 Sep; 194(5):888-892. PubMed ID: 34337744
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
3. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
[TBL] [Abstract][Full Text] [Related]
4. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
[TBL] [Abstract][Full Text] [Related]
5. How I investigate minimal residual disease in acute lymphoblastic leukemia.
Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
[TBL] [Abstract][Full Text] [Related]
6. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
Kolenova A; Hikkel I; Ilencikova D; Hikkelova M; Sejnova D; Kaiserova E; Cizmar A; Puskacova J; Bubanska E; Oravkinova I; Gencik M
Neoplasma; 2010; 57(6):552-61. PubMed ID: 20845994
[TBL] [Abstract][Full Text] [Related]
8. Low frequency of clonotypic Ig and T-cell receptor gene rearrangements in t(4;11) infant acute lymphoblastic leukaemia and its implication for the detection of minimal residual disease.
Peham M; Panzer S; Fasching K; Haas OA; Fischer S; Marschalek R; Gadner H; Panzer-Grümayer ER
Br J Haematol; 2002 May; 117(2):315-21. PubMed ID: 11972513
[TBL] [Abstract][Full Text] [Related]
9. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
Szczepański T; Flohr T; van der Velden VH; Bartram CR; van Dongen JJ
Best Pract Res Clin Haematol; 2002 Mar; 15(1):37-57. PubMed ID: 11987915
[TBL] [Abstract][Full Text] [Related]
10. Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
Popov A; Tsaur G; Verzhbitskaya T; Riger T; Permikin Z; Demina A; Mikhailova E; Shorikov E; Arakaev O; Streneva O; Khlebnikova O; Makarova O; Miakova N; Fominikh V; Boichenko E; Kondratchik K; Ponomareva N; Novichkova G; Karachunskiy A; Fechina L
Br J Haematol; 2023 May; 201(3):510-519. PubMed ID: 34970734
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
12. [Detection of minimal residual disease in childhood acute lymphoblastic leukemia by using real-time quantitative PCR].
Zhang YT; Luo ZF; Fang JP; Guo HX; Huang K; Li CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1235-9. PubMed ID: 21129267
[TBL] [Abstract][Full Text] [Related]
13. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
[TBL] [Abstract][Full Text] [Related]
14. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
15. Polymerase chain reaction (PCR)- and reverse transcription PCR-based minimal residual disease detection in long-term follow-up of childhood acute lymphoblastic leukaemia.
Gameiro P; Moreira I; Yetgin S; Papaioannou M; Potter MN; Prentice HG; Hoffbrand AV; Foroni L
Br J Haematol; 2002 Dec; 119(3):685-96. PubMed ID: 12437645
[TBL] [Abstract][Full Text] [Related]
16. Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease.
Szczepański T; Beishuizen A; Pongers-Willemse MJ; Hählen K; Van Wering ER; Wijkhuijs AJ; Tibbe GJ; De Bruijn MA; Van Dongen JJ
Leukemia; 1999 Feb; 13(2):196-205. PubMed ID: 10025893
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
[TBL] [Abstract][Full Text] [Related]
18. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines.
van der Velden VHJ; Dombrink I; Alten J; Cazzaniga G; Clappier E; Drandi D; Eckert C; Fronkova E; Hancock J; Kotrova M; Kraemer R; Montonen M; Pfeifer H; Pott C; Raff T; Trautmann H; Cavé H; Schäfer BW; van Dongen JJM; Trka J; Brüggemann M;
Leukemia; 2024 Jun; 38(6):1315-1322. PubMed ID: 38744919
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
20. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR.
van der Velden VH; van Dongen JJ
Methods Mol Biol; 2009; 538():115-50. PubMed ID: 19277574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
